Our main focus is translational studies in B-cell lymphoma, a malignancy that arise in B-lymphocytes of the adaptive immune system. We characterize mutational and genomic alterations to identify events associated with poor outcome, and map tumor clonal evolution patterns. A key interest is also studies of immunosuppression in the tumor microenvironment (TME). Different forms of immunotherapy are becoming cornerstones in treatment of cancer, but novel therapeutic strategies need to overcome the multitude of immune escape mechanisms operating in TME. To identify key immunosuppressive elements, we characterize patient biopsies using single-cell sequencing, high-dimensional fluorescent flow- and mass cytometry and mass cytometry imaging technologies.

Ongoing projects are:

• Clonal evolution and identification of early genetic changes in lymphomagenesis
• Mechanisms of immune escape and immunosuppression in tumor cells and the tumor microenvironment
• Immune cell subsets/cell states in the tumor microenvironment that are linked to resistance to immunotherapy
• Diversity and role of regulatory T cells in anti-tumor immunity

The group is a member of the KG Jebsen Centre for B-cell malignancies and the Centre of Excellence, Precision Immunotherapy Alliance (PRIMA).

Follow us on Twitter: https://twitter.com/LabMyklebust

Group leader: June H. Myklebust 
Email: j.h.myklebust@medisin.uio.no, 
Phone: +47 99109677

Visiting Address: Institute for Cancer Research at Oslo University Hospital, The Research building, 3rd floor, Ullernchausseen 70, 0379 Oslo.